The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

Table 10

Comparison of early phase studies of novel agents in relapsed and refractory Hodgkin’s lymphoma. Abbreviations: PR: partial response; CR: complete response; ORR: overall response rate; IL2-R: interleukin 2 receptor; HDAC: histone deacetylase; mTOR: mammalian target of rapamycin.

Novel agent; (author)	Target	No. of Pts	Route	Phase	PR (%)	CR (%)	ORR (%)
SGN30; (Forero-Torres 2009)	CD30	38	IV	II	0	0	0
MDX060; (Ansell 2007)	CD30	47	IV	I/II	4	4	8
SGN35; (Younes 2008)	CD30	44	IV	I	14	25	39
SGN35; (Bartlett 2009)	CD30	17	IV	I	6	41	47
CHT25; (Dancey 2009)	IL2-R radioimmunotherapy	9	IV	I	33	33	66
MGCD0103; (Younes 2007)	HDAC class I	21	Oral	II	29	9	38
Panobinostat; (Dickinson 2009)	Pan HDAC	13	Oral	I/II	54	0	54
Panobinostat; (Younes 2009)	Pan HDAC	27	Oral	II	15	4	19
Vorinostat; (Kirschbaum 2007)	Pan HDAC	25	Oral	II	4	0	4
Everolimus; (Johnston)	mTOR	19	Oral	II	42	5	47
Bortezomib; (Younes 2006)	Proteasome	14	IV	II	7	0	7
Bortezomib; (Blum 2007)	Proteasome	30	IV	II	0	0	0
Rituximab; (Rehwald 2003)	CD20	14	IV	II	57	29	86
Rituximab; (Younes 2003)	CD20	22	IV	II	18	5	22
Lenalidomide; (Boll 2009)	Immunomodulator	12	Oral	II	23	8	50
Lenalidomide; (Kuruvilla)	Immunomodulator	17	Oral	II	47	6	53